This content is machine translated Chronic lymphocytic leukemia (CLL) One year of first-line therapy for CLL for the prospect of more than 5 years of treatment freedom¹ The BCL2 inhibitor venetoclax has been approved in Switzerland as a first-line therapy for chronic lymphocytic leukemia (CLL) since November 16, 2023 [2]. This is based on the results of…
View Post 7 min This content is machine translated Pediatric hematology and oncology Acute childhood leukemias: an update. A child with unexplained cytopenia and additional symptoms such as fever, lymphadenopathy, or hepatosplenomegaly should be generously and rapidly referred to a center. Hyperleukocytosis, tumor lysis syndrome, and mediastinal tumor…
